Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Debt to Equity (2016 - 2023)

Marker Therapeutics (MRKR) has disclosed Debt to Equity for 7 consecutive years, with $0.01 as the latest value for Q1 2023.

  • Quarterly Debt to Equity changed N/A to $0.01 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $0.01 through Mar 2023, changed N/A year-over-year, with the annual reading at $0.13 for FY2022, N/A changed from the prior year.
  • Debt to Equity for Q1 2023 was $0.01 at Marker Therapeutics, down from $0.13 in the prior quarter.
  • The five-year high for Debt to Equity was $0.29 in Q2 2022, with the low at $0.0 in Q4 2019.
  • Average Debt to Equity over 3 years is $0.08, with a median of $0.0 recorded in 2019.
  • Peak annual rise in Debt to Equity hit 14.84% in 2019, while the deepest fall reached 98.26% in 2019.
  • Over 3 years, Debt to Equity stood at $0.0 in 2019, then soared by 18038.53% to $0.13 in 2022, then tumbled by 95.2% to $0.01 in 2023.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.01, $0.13, and $0.22 for Q1 2023, Q4 2022, and Q3 2022 respectively.